(Adds revenue, guidance)
(Reuters) -Italian medical diagnostics group DiaSorin on Tuesday posted a 6% jump in nine-month adjusted core profit to 292 million euros ($318.46 million) at constant exchange rates, driven by its immunodiagnostic segment.
The group’s nine-month overall revenue grew to 583 million euros compared to last year’s results of 846 million euros, driven by the excellent performance of CLIA speciality tests in the immunodiagnostics segment, which rose 10% yearly, the company said in a statement.
It slightly lifted its 2024 revenue guidance, forecasting now a 7% increase in ex-Covid revenues, instead of the previously expected increase between 6 and 7%. The company confirmed its guidance of a 33% increase in adjusted core profit margin.
($1 = 0.9169 euros)
(Reporting by Michela Stasio in GdanskEditing by David Goodman, Alexandra Hudson)
